A former pharmaceutical toxicology executive has attracted international attention after testifying at a German parliamentary COVID-19 review hearing.His comments raised questions about vaccine development timelines and post-authorisation safety monitoring.Reviewing Pfizer-BioNTech’s Comirnaty vaccine approval, he slammed skipped safety tests for carcinogenicity and reproductive toxicity, calling the rushed process a “vaccination tragedy” unfit even for a deadly virus like Ebola.Sterz highlighted 2,133 deaths reported to the Paul Ehrlich Institute, applying a US-style underreporting factor of 30 to estimate 20,000–60,000 vaccine-linked fatalities in Germany alone.While his critique fuels debate on mRNA safety, official reports note temporal associations, not proven causation, urging caution amid ongoing inquiries.Below Dr Helmut Sterz ( Former Pfizer Chief Toxicologist ) speaks at German Covid Inquiry on the mRNA vaccineThe discussion gained global attention after a short clip from the hearing circulated widely on social media and was amplified by high-profile figures, including Elon Musk, who questioned why the testimony was not receiving broader media coverage.In a post on X, the claim was made that the witness suggested an estimated 20,000 to 60,000 deaths in Germany could be associated with COVID-19 vaccination, and questioned why such assertions were not receiving broader mainstream media coverage.Elon Musk also commented separately, stating that vaccine dosing and repeat administration may have been excessive, and shared personal remarks about his own experience with COVID-19 infection and vaccination side effects.The testimonyDr. Helmut Sterz, a retired toxicologist who previously worked in the pharmaceutical industry and left his executive roles in 2007, addressed a German parliamentary COVID-19 inquiry committee.He argued that certain preclinical safety studies—such as long-term carcinogenicity and reproductive toxicity testing—were limited or not fully completed prior to the emergency authorization of COVID-19 mRNA vaccines.Sterz also cited figures from Germany’s vaccine safety monitoring system, managed by the Paul-Ehrlich-Institut, stating that more than 2,000 deaths had been reported following vaccination with the Pfizer-BioNTech COVID-19 vaccine.He further applied a statistical multiplier derived from a US vaccine adverse event reporting estimate to suggest that actual vaccine-related deaths could be significantly higher than reported figures.How health authorities interpret the dataPublic health experts stress that vaccine safety reporting systems record events occurring after vaccination, not confirmed vaccine-caused outcomes.Reports of death following vaccination are investigated but are not, by themselves, evidence of causation.The multiplier used by Sterz is based on historical assumptions about underreporting in US vaccine surveillance systems. Experts caution that such estimates cannot be directly applied to Germany due to differences in healthcare infrastructure, reporting practices, and surveillance methodologies.Regulatory contextThe European Medicines Agency approved COVID-19 vaccines under emergency procedures following large-scale clinical trials.Regulators have consistently stated that the benefits of vaccination in preventing severe COVID-19 disease and death outweigh known risks.Rare adverse events, including myocarditis in specific age groups, have been identified and incorporated into updated safety guidance. However, large population studies have generally found that such events remain uncommon, and that COVID-19 infection itself carries higher risks of similar complications.Broader scientific findingsLarge epidemiological studies conducted across multiple countries have found that vaccination campaigns were associated with reduced rates of severe illness and excess mortality during the pandemic period.Researchers continue to study long-term safety monitoring data, but no peer-reviewed analysis has confirmed claims of tens of thousands of vaccine-attributed deaths in Germany based on passive reporting systems.Ongoing debateThe testimony has reignited discussion about how quickly COVID-19 vaccines were developed, the scope of pre-authorization safety testing, and how adverse events are monitored after deployment.While these questions remain part of ongoing scientific and regulatory review, health authorities distinguish between hypotheses raised in testimony and conclusions supported by population-level evidence.